OsteoRemedies
OsteoRemedies is a Memphis, TN-based orthopedic medical device company that develops and sells pre-fabricated antibiotic-eluting spacers, bone cements, surgical irrigation solutions, and debridement devices for the two-stage surgical treatment of periprosthetic joint infections in hip, knee, and shoulder arthroplasty, sold to U.S. hospitals and orthopedic surgeons.
- Company typePrivate
- Founded2013
- HeadquartersMemphis, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What OsteoRemedies does
OsteoRemedies, LLC is a Memphis, Tennessee-based orthopedic medical device company founded in September 2013 by Chris Hughes and operating as a subsidiary of Demetra Holding. The company develops and sells a curated portfolio of products focused on the surgical treatment of periprosthetic joint infection (PJI) in hip, knee, and shoulder arthroplasty, where two-stage revision is the standard of care. Its flagship REMEDY® Spacer System comprises pre-fabricated antibiotic-eluting temporary implants (180-day or less implantation) with predictable 6-month antibiotic elution profiles, available across hip, knee, shoulder, and stemmed knee configurations including the REMEDY Poly+Plus Stemmed Knee introduced in 2026. Supporting the spacer platform are dual-antibiotic bone cements (SPECTRUM® GV with gentamicin and vancomycin, and UNITE® AB), surgical irrigation solutions (XPERIENCE® and BIOWASH™), the BIOBRUSH™ powered debridement device (which removes 3.5x more biofilm than manual brushing), the OSTEOBOOST® Select resorbable bead kit, and BLASTX® antimicrobial wound gel.
The business model is a classic specialty medical device hardware sales motion: products are sold to U.S. hospitals and orthopedic surgeons via an enterprise field sales force led by a VP of Sales, supplemented by a distributor portal and direct customer service. Pricing is quote-based through sales representatives with no public list pricing. Go-to-market emphasizes surgeon education (videos, technique guides, IFU documents), KOL collaboration with academic institutions such as Campbell Clinic, RUSH University Medical Center, and Indiana University School of Medicine, and active participation in major orthopedic conferences (AAOS, AAHKS, ASES Revision Course). Revenue is generated entirely within the United States, and the company holds four U.S. patents on BLASTX wound gel technology plus FDA clearances including a 2024 expanded indication for SPECTRUM GV Bone Cement in revision hip arthroplasty. The bone cement market is reported at $657.8M in 2024 with projected growth to over $1.2B by 2035, providing context for the company's addressable opportunity.
OsteoRemedies firmographics
Firmographics- Name
- OsteoRemedies
- Legal name
- OsteoRemedies, LLC
- Website
- https://osteoremedies.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- OsteoRemedies is a Memphis, TN-based orthopedic medical device company that develops and sells pre-fabricated antibiotic-eluting spacers, bone cements, surgical irrigation solutions, and debridement devices for the two-stage surgical treatment of periprosthetic joint infections in hip, knee, and shoulder arthroplasty, sold to U.S. hospitals and orthopedic surgeons.
- Ownership category
- akta.pro rank
OsteoRemedies industry classification
Industry- Product category
- Orthopedic Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle) (HLAHAEAA)
- akta.pro secondary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
Keywords
Where OsteoRemedies is headquartered
LocationHeadquarters
- HQ city
- Memphis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
OsteoRemedies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations
Revenue model
- Medical Device Sales: Sale of orthopedic medical devices including antibiotic-eluting spacers, bone cement products, surgical irrigation solutions, and wound care products. Products sold to hospitals and orthopedic surgeons for use in two-stage revision procedures for periprosthetic joint infections.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based pricing through sales representatives |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
OsteoRemedies product offering
Product offeringCore offering
OsteoRemedies develops, manufactures, and sells pre-fabricated antibiotic-eluting spacers (hip, knee, shoulder, stemmed knee variants) used in two-stage treatment of periprosthetic joint infection (PJI). The portfolio is anchored by the REMEDY® Spacer System and complemented by dual-antibiotic bone cements (SPECTRUM® GV and UNITE® AB), surgical irrigation solutions (XPERIENCE and BIOWASH), the BIOBRUSH powered debridement device, the OSTEOBOOST bone void filler, and BLASTX antimicrobial wound gel, sold to hospitals and orthopedic surgeons in the United States.
Product overview
OsteoRemedies is a Memphis, TN-based medical device company specializing in orthopedic revision and infection remedies. The company offers a portfolio of products centered on its REMEDY Spacer System platform, which includes pre-fabricated antibiotic-eluting spacers for hip (REMEDY HIP, REMEDY SPECTRUM GV HIP), knee (REMEDY KNEE, REMEDY STEMMED KNEE, REMEDY POLY+PLUS STEMMED KNEE), and shoulder (REMEDY SHOULDER) applications. Supporting the spacer portfolio are bone cements (SPECTRUM GV BONE CEMENT, UNITE AB BONE CEMENT), surgical irrigation solutions (XPERIENCE, BIOWASH), the BIOBRUSH powered debridement device, the OSTEOBOOST SELECT resorbable bead kit, and BLASTX antimicrobial wound gel. The company was founded in September 2013 and celebrated its 10-year anniversary in 2025.
Differentiator
Problem solved
Functional benefit
Brands
- REMEDY: Product line of antibiotic-eluting spacer systems for hip, knee, and shoulder joint replacement revision procedures
- SPECTRUM
- UNITE
- XPERIENCE
- BIOWASH
- BIOBRUSH
- BLASTX
- OSTEOBOOST
- INTERSPACE
Products and services
- REMEDY® Hip Spacer Pre-fabricated antibiotic-eluting hip spacer used as a temporary implant (180 days or less) in two-stage treatment of infected total hip arthroplasty; allows basic joint mobility and releases antibiotics into the joint area.
- REMEDY® Knee Spacer Pre-fabricated antibiotic-eluting knee spacer used as a temporary implant (180 days or less) for two-stage treatment of infected total knee arthroplasty; allows basic joint mobility and delivers predictable 6-month antibiotic elution.
- REMEDY® Shoulder Spacer Pre-fabricated antibiotic-eluting shoulder spacer used as a temporary implant (180 days or less) for two-stage treatment of infected total shoulder arthroplasty, allowing basic joint mobility with modular stem options for anatomical fit.
- REMEDY® Stemmed Knee Spacer Stemmed knee spacer option providing modularity and size interchangeability for knee PJI cases that require additional stability during the two-stage treatment interval.
- REMEDY® Poly+Plus Stemmed Knee Spacer Advanced stemmed knee spacer combining antibiotic-eluting PMMA with XLPE (cross-linked polyethylene) for improved joint articulation during the interim period (temporary implantation up to 180 days) before permanent implant placement.
- INTERSPACE® Spacer System Modular spacer system providing options for hip, knee, and shoulder applications with interchangeable components for two-stage PJI treatment.
- SPECTRUM® GV Bone Cement Dual-antibiotic-loaded bone cement containing Gentamicin and Vancomycin with predictable elution profile, FDA-cleared for revision hip arthroplasty and used in PJI management.
- UNITE® AB Bone Cement Antibiotic bone cement formulation specifically designed to work in conjunction with REMEDY spacer systems for use in revision and infection procedures.
- REMEDY SPECTRUM® GV Hip Spacer Hip spacer variant incorporating SPECTRUM GV dual-antibiotic bone cement (Gentamicin + Vancomycin) for enhanced antimicrobial efficacy in periprosthetic joint infection treatment of the hip.
- BIOWASH™ Surgical Irrigation+ Powered cleansing surgical irrigation product containing Citric Acid, Sodium Lauryl Sulfate, and Sodium Citrate, formulated for removal of microorganisms with residual product allowed to safely remain in the wound.
- XPERIENCE® Surgical Irrigation Solution Clinically evaluated surgical irrigation solution requiring no rinse, designed for manual or powered irrigation with improved physician workflow.
- BIOBRUSH™ Powered Debridement Device Powered surgical debridement device for use in revision procedures, clinically shown to remove 3.5x more biofilm compared to manual surgical scrub brushes for enhanced infection management.
- OSTEOBOOST® SELECT™ RBK (Resorbable Bead Kit) Resorbable bead kit osteoconductive synthetic bone graft used to fill bone voids and gaps, with over 10 years of clinical use and 510(k) clearance for extremities, spine, pelvis, and cranium.
- BLASTX® Antimicrobial Wound Gel Broad-spectrum antimicrobial wound gel that maintains a moist wound environment conducive to healing, is biocompatible per ISO 10993-1, and prevents bacterial growth within the gel.
Quantifiable outcome
- Removes 3.5x more biofilm compared to manual surgical scrub brush (BIOBRUSH)
- +2 more outcomes
Companies that use OsteoRemedies
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles2 records
OsteoRemedies technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
OsteoRemedies partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Next ScienceminorXPERIENCE and BLASTX products purchased from Next Science by Demetra Holding. Products now distributed in the United States through OsteoRemedies, LLC. Next Science sold the XPERIENCE and BLASTX assets to Demetra Holding.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
OsteoRemedies competitors and assessment
Company assessmentBroad incumbents
- B. Braun: Broad surgical, orthopedic, and infection-prevention medical device manufacturer whose Aesculap division addresses joint infection, bone cement, and irrigation in overlapping clinical workflows.
- DePuy Synthes (Johnson & Johnson): J&J's orthopedic and trauma franchise offering hip/knee reconstruction implants, trauma fixation, and infection management as part of a vastly broader portfolio that nonetheless overlaps with OsteoRemedies' PJI use cases.
- DJO (Encompass): Broad orthopedic and musculoskeletal products company whose extremities, bracing, and surgical implant lines overlap with OsteoRemedies' orthopedic surgical franchise though DJO is more diversified.
Direct peers
- Smith & Nephew: Global orthopedics and advanced wound management company that sells antibiotic-loaded bone cements, joint reconstruction implants, and antimicrobial wound products directly competing with OsteoRemedies' spacer, cement, and wound gel portfolio.
- Zimmer Biomet: One of the largest hip and knee reconstruction franchises globally with bone cement, antibiotic spacers (legacy Biomet), and revision surgical solutions that compete head-to-head with OsteoRemedies' REMEDY spacers and SPECTRUM bone cement.
- Wright Medical (now part of Stryker): Pre-acquisition Wright Medical ran extremities/upper limb and infection products staffed by executives now at OsteoRemedies (e.g., COO Eric Stookey); its former extremities-biologics franchise provides a direct functional comparator.
- Heraeus Medical: German specialist whose PALACOS brand is the historical gold-standard antibiotic-loaded bone cement for joint arthroplasty, making it the closest direct competitor to OsteoRemedies' SPECTRUM GV bone cement in revision settings.
- Exactech: Orthopedic implant specialist offering hip, knee, and shoulder reconstruction components including revision offerings that compete with OsteoRemedies' joint-revision focus on a smaller-scale specialty basis.
- Tecres: Italian specialty manufacturer of pre-formed antibiotic-loaded temporary spacers (Spacer K, Spacer G) for two-stage PJI treatment; the closest specialist peer to OsteoRemedies' REMEDY pre-fabricated spacer concept.
- Stryker: Major orthopedic medical device company offering hip and knee implants as well as antibiotic bone cement and infection management products used in PJI revision procedures alongside OsteoRemedies' REMEDY line.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
OsteoRemedies social profiles
Digital presenceOsteoRemedies compliance and trust
Trust signalCompliance2 records
OsteoRemedies financial estimates
Financial estimateRevenue estimate
Valuation estimate
OsteoRemedies leadership team
Management profileNumber of profiles
Profiles9 records
OsteoRemedies funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OsteoRemedies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OsteoRemedies
What does OsteoRemedies do?
OsteoRemedies develops, manufactures, and sells pre-fabricated antibiotic-eluting spacers (hip, knee, shoulder, stemmed knee variants) used in two-stage treatment of periprosthetic joint infection (PJI). The portfolio is anchored by the REMEDY® Spacer System and complemented by dual-antibiotic bone cements (SPECTRUM® GV and UNITE® AB), surgical irrigation solutions (XPERIENCE and BIOWASH), the BIOBRUSH powered debridement device, the OSTEOBOOST bone void filler, and BLASTX antimicrobial wound gel, sold to hospitals and orthopedic surgeons in the United States.
Is OsteoRemedies a public or private company?
OsteoRemedies is a private company. It is classified as corporate owned and is currently operating.
When was OsteoRemedies founded?
OsteoRemedies was founded in 2013. It employs 11 to 50 people.
Where is OsteoRemedies based?
OsteoRemedies is headquartered in Memphis, United States, in the North America region.
How does OsteoRemedies make money?
One revenue line is on record: medical Device Sales.
Who are OsteoRemedies's main competitors?
Broad incumbents on record are B. Braun, DePuy Synthes (Johnson & Johnson) and DJO (Encompass). Direct peers are Smith & Nephew, Zimmer Biomet, Wright Medical (now part of Stryker), Heraeus Medical, Exactech, Tecres and Stryker.
Does OsteoRemedies have an API?
No public API is recorded for OsteoRemedies.
What industry is OsteoRemedies in?
OsteoRemedies's product category is Orthopedic Medical Devices. Its primary akta.pro industry code is HLAHAEAA, Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle), with a secondary code of HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 339113 and its SIC code is 3842.